Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Praxis Precision Medicines
Biotech
Praxis epilepsy drug reduces seizures in phase 2 trial
Participants who received relutrigine saw an average 46% reduction in their seizures during the double-blind part of the study.
James Waldron
Sep 3, 2024 10:21am
Praxis' epilepsy drug hits in phase 2, sparking stock rise
Mar 26, 2024 10:24am
Praxis share price halved by tremor fail but still plans phase 3
Mar 3, 2023 9:05am
Praxis ends year on high with $100M biobucks UCB deal
Dec 14, 2022 5:29am
Praxis acts fast as depression drug flunks late-phase test
Jun 6, 2022 9:40am
FDA slaps clinical hold on Praxis’ leading epilepsy candidate
Apr 29, 2022 12:31pm